Valued at USD 71.38 billion in 2024, the hematologic malignancies therapeutics market is projected to reach USD 76.63 billion in 2025 and USD 148.15 billion by 2034, growing at a CAGR of 7.6% during the forecast period 2025–2034. North America held the largest regional position in 2024. Key players include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd.,...